Cargando…

Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

INTRODUCTION: Recently, studies have demonstrated that the addition of bevacizumab to chemotherapy could be associated with better outcomes in patients with advanced non-small cell lung cancer (NSCLC). However, the benefit seems to be dependent on the drugs used in the chemotherapy regimens. This sy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lima, André Bacellar Costa, Macedo, Ligia T., Sasse, André Deeke
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3149053/ https://www.ncbi.nlm.nih.gov/pubmed/21829644 http://dx.doi.org/10.1371/journal.pone.0022681

Ejemplares similares

Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups
por: Macedo, Ligia Traldi, et al.
Publicado: (2012)

Is there a role for consolidative radiotherapy in the treatment of aggressive and localized Non-Hodgkin Lymphoma? A systematic review with meta-analysis
por: dos Santos, Lucas Vieira, et al.
Publicado: (2012)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Optimal duration of androgen deprivation therapy following radiation therapy in intermediate- or high-risk non-metastatic prostate cancer: A systematic review and meta-analysis
por: Leal, Frederico, et al.
Publicado: (2015)

Comparison of bevacizumab plus chemotherapy with chemotherapy alone in advanced non-small-lung cancer patients
por: Tang, Ning, et al.
Publicado: (2016)

Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review
por: Sasse, André D, et al.
Publicado: (2012)

Adjuvant therapy for locally advanced renal cell cancer: A systematic review with meta-analysis
por: Scherr, Adolfo JO, et al.
Publicado: (2011)

Systematic Review and Network Meta-Analysis of Bevacizumab Plus First-Line Topotecan-Paclitaxel or Cisplatin-Paclitaxel Versus Non–Bevacizumab-Containing Therapies in Persistent, Recurrent, or Metastatic Cervical Cancer
por: Rosen, Virginia M., et al.
Publicado: (2017)

Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials
por: Lai, Xi-Xi, et al.
Publicado: (2016)

Direct Comparison Between the Addition of Pembrolizumab or Bevacizumab for Chemotherapy-Based First-Line Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer Lacking Driver Mutations
por: Liao, Jiatao, et al.
Publicado: (2021)

Magnitude of risks and benefits of the addition of bevacizumab to chemotherapy for advanced breast cancer patients: Meta-regression analysis of randomized trials
por: Cuppone, Federica, et al.
Publicado: (2011)

Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer
por: Reck, Martin, et al.
Publicado: (2020)

Effectiveness and Safety of Adding Bevacizumab to Platinum-Based Chemotherapy as First-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Liu, Yi, et al.
Publicado: (2021)

Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis
por: Xiao, Xian, et al.
Publicado: (2022)

Bevacizumab/PD-1 inhibitor plus chemotherapy as first-line treatment of advanced non-squamous non-small-cell lung cancer
por: Wang, Jing, et al.
Publicado: (2023)

Protective effect of bevacizumab on chemotherapy-related acute exacerbation of interstitial lung disease in patients with advanced non-squamous non-small cell lung cancer
por: Hamada, Shohei, et al.
Publicado: (2019)

Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab
por: Stinchcombe, Thomas E
Publicado: (2007)

The Role of Combination Maintenance with Pemetrexed and Bevacizumab for Advanced Stage Nonsquamous Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
por: Shan, Feiyu, et al.
Publicado: (2018)

The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final results of AVALANCHE, an observational cohort study
por: Tolnay, Edina, et al.
Publicado: (2019)

Sequential or concomitant chemotherapy with hypofractionated radiotherapy for locally advanced non-small cell lung cancer: a meta-analysis of randomized trials
por: Viani, Gustavo Arruda, et al.
Publicado: (2021)

Efficacy and Safety of Bevacizumab-Combined Chemotherapy for Advanced and Recurrent Endometrial Cancer: A Systematic Review and Meta-analysis
por: Chen, Hui, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
por: Aravantinos, Gerasimos, et al.
Publicado: (2014)

Efficacy and safety of bevacizumab combined with EGFR‐TKIs in advanced non‐small cell lung cancer: A meta‐analysis
por: Yang, Yifan, et al.
Publicado: (2021)

Combined Immunotherapy with Chemotherapy versus Bevacizumab with Chemotherapy in First-Line Treatment of Driver-Gene-Negative Non-Squamous Non-Small Cell Lung Cancer: An Updated Systematic Review and Network Meta-Analysis
por: Chai, Yue, et al.
Publicado: (2022)

Bevacizumab treatment for advanced non-small cell lung cancer: A case report
por: FAN, YUN, et al.
Publicado: (2013)

Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer: A systematic review and meta-analysis
por: Kong, Ying, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta-analysis
por: Zhang, Shu, et al.
Publicado: (2016)

Efficacy and safety of bevacizumab biosimilar compared with reference bevacizumab in locally advanced and advanced non-small cell lung cancer patients: A retrospective study
por: Zhao, Zhiting, et al.
Publicado: (2023)

Anti-PD-1 Therapy plus Chemotherapy and/or Bevacizumab as Second Line or later Treatment for Patients with Advanced Non-Small Cell Lung Cancer
por: Zhang, Fan, et al.
Publicado: (2020)

The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?
por: Kruse, Vibeke, et al.
Publicado: (2013)

Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis
por: Hu, Binbin, et al.
Publicado: (2018)

Comparing Efficacy of Erlotinib and Bevacizumab Combination with Erlotinib Monotherapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
por: Sakharkar, Prashant, et al.
Publicado: (2023)

Acupuncture or moxibustion adjuvant chemotherapy for advanced non-small cell lung cancer: Systematic review and network meta-analysis
por: Wang, Shiheng, et al.
Publicado: (2023)

First-generation EGFR-TKI plus bevacizumab and chemotherapy for advanced EGFR-mutated non-squamous non-small-cell lung cancer: a retrospective study
por: Wu, Yahua, et al.
Publicado: (2023)

Effect of Osimertinib in Combination With Chemotherapy and Bevacizumab for Untreated Epidermal Growth Factor Receptor–Mutated Advanced Non-Small-Cell Lung Cancer: Case Report
por: Qin, Haifeng, et al.
Publicado: (2021)

Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis
por: Botrel, Tobias Engel Ayer, et al.
Publicado: (2016)

Antipodal universes in the topology H$^{3}$ x R and S$^{3}$ x R
por: Deeke Sasse, F, et al.
Publicado: (1993)

Bevacizumab combined with chemotherapy for ovarian cancer: A protocol for systematic review and meta-analysis
por: Liao, Ting, et al.
Publicado: (2021)

Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG 5910L)
por: Takeda, Masayuki, et al.
Publicado: (2012)

PD-1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in patients with advanced non-squamous non-small-cell lung cancer: a pooled analysis of three randomised trials
por: Meng, Xiangjiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_savn1de2k01mp8f5srq8f8l0ta